Memantine in Patients With Chronic Glaucoma
Sponsor
Allergan (Industry)
Overall Status
Completed
CT.gov ID
NCT00168350
Collaborator
(none)
1,179
78
Study Details
Study Description
Brief Summary
Randomized double-masked clinical trial of memantine in patients with glaucoma
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
1179 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Study Start Date
:
Mar 1, 2000
Actual Primary Completion Date
:
Sep 1, 2006
Actual Study Completion Date
:
Sep 1, 2006
Outcome Measures
Primary Outcome Measures
- Progression of glaucoma []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 82 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
glaucoma damage on examination of visual field and optic disc
-
good visual acuity (with glasses if needed)
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Allergan
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00168350
Other Study ID Numbers:
- 192944-005
First Posted:
Sep 15, 2005
Last Update Posted:
Nov 4, 2010
Last Verified:
Nov 1, 2010